{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:34:28Z","timestamp":1791232468971,"version":"4.1.0"},"reference-count":54,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In most patients with systemic mastocytosis (SM), including aggressive SM and mast cell leukemia (MCL), neoplastic cells express the oncogenic KIT mutation D816V. KIT D816V is associated with constitutive tyrosine kinase (TK) activity and thus represents an attractive drug target. However, imatinib and most other TK inhibitors fail to block the TK activity of KIT D816V. We show that the novel TK-targeting drugs PKC412 and AMN107 counteract TK activity of D816V KIT and inhibit the growth of Ba\/F3 cells with doxycycline-inducible expression of KIT D816V as well as the growth of primary neoplastic mast cells and HMC-1 cells harboring this KIT mutation. PKC412 was a superior agent with median inhibitory concentration (IC50) values of 50 to 250 nM without differences seen between HMC-1 cells exhibiting or lacking KIT D816V. By contrast, AMN107 exhibited more potent effects in KIT D816V- HMC-1 cells. Corresponding results were obtained with Ba\/F3 cells exhibiting wild-type or D816V-mutated KIT. The growth-inhibitory effects of PKC412 and AMN107 on HMC-1 cells were associated with induction of apoptosis and down-regulation of CD2 and CD63. PKC412 was found to cooperate with AMN107, imatinib, and cladribine (2CdA) in producing growth inhibition in HMC-1, but synergistic drug interactions were observed only in cells lacking KIT D816V. Together, PKC412 and AMN107 represent promising novel agents for targeted therapy of SM. (Blood. 2006;107: 752-759)<\/jats:p>","DOI":"10.1182\/blood-2005-07-3022","type":"journal-article","created":{"date-parts":[[2005,9,28]],"date-time":"2005-09-28T03:33:43Z","timestamp":1127878423000},"page":"752-759","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":205,"title":["PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects"],"prefix":"10.1182","volume":"107","author":[{"given":"Karoline V.","family":"Gleixner","sequence":"first","affiliation":[{"name":"From the Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence in Clinical and Experimental Oncology (CLEXO), Institute of Immunology, and Institute of Histology and Embryology, Medical University of Vienna, Austria; and Novartis Pharma, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Mayerhofer","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence in Clinical and Experimental Oncology (CLEXO), Institute of Immunology, and Institute of Histology and Embryology, Medical University of Vienna, Austria; and Novartis Pharma, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl J.","family":"Aichberger","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence in Clinical and Experimental Oncology (CLEXO), Institute of Immunology, and Institute of Histology and Embryology, Medical University of Vienna, Austria; and Novartis Pharma, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Derdak","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence in Clinical and Experimental Oncology (CLEXO), Institute of Immunology, and Institute of Histology and Embryology, Medical University of Vienna, Austria; and Novartis Pharma, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Sonneck","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence in Clinical and Experimental Oncology (CLEXO), Institute of Immunology, and Institute of Histology and Embryology, Medical University of Vienna, Austria; and Novartis Pharma, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Bo\u0308hm","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence in Clinical and Experimental Oncology (CLEXO), Institute of Immunology, and Institute of Histology and Embryology, Medical University of Vienna, Austria; and Novartis Pharma, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gruze","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence in Clinical and Experimental Oncology (CLEXO), Institute of Immunology, and Institute of Histology and Embryology, Medical University of Vienna, Austria; and Novartis Pharma, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puchit","family":"Samorapoompichit","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence in Clinical and Experimental Oncology (CLEXO), Institute of Immunology, and Institute of Histology and Embryology, Medical University of Vienna, Austria; and Novartis Pharma, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Manley","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence in Clinical and Experimental Oncology (CLEXO), Institute of Immunology, and Institute of Histology and Embryology, Medical University of Vienna, Austria; and Novartis Pharma, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriano","family":"Fabbro","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence in Clinical and Experimental Oncology (CLEXO), Institute of Immunology, and Institute of Histology and Embryology, Medical University of Vienna, Austria; and Novartis Pharma, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried F.","family":"Pickl","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence in Clinical and Experimental Oncology (CLEXO), Institute of Immunology, and Institute of Histology and Embryology, Medical University of Vienna, Austria; and Novartis Pharma, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sillaber","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence in Clinical and Experimental Oncology (CLEXO), Institute of Immunology, and Institute of Histology and Embryology, Medical University of Vienna, Austria; and Novartis Pharma, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine I, Division of Hematology and Hemostaseology, Center of Excellence in Clinical and Experimental Oncology (CLEXO), Institute of Immunology, and Institute of Histology and Embryology, Medical University of Vienna, Austria; and Novartis Pharma, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111814303061900_REF1","doi-asserted-by":"crossref","unstructured":"Reilly JT. Class III receptor tyrosine kinases: role in leukaemogenesis. Br J Haematol.2002;116: 744-757.","DOI":"10.1046\/j.0007-1048.2001.03294.x"},{"key":"2019111814303061900_","doi-asserted-by":"crossref","unstructured":"Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev.2003;55: 401-423.","DOI":"10.1124\/pr.55.3.4"},{"key":"2019111814303061900_REF3","doi-asserted-by":"crossref","unstructured":"Pardanani A, Tefferi A. Imatinib targets other than bcr\/abl and their clinical relevance in myeloid disorders. Blood.2004;104: 1931-1939.","DOI":"10.1182\/blood-2004-01-0246"},{"key":"2019111814303061900_","doi-asserted-by":"crossref","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science.2004;305: 399-401.","DOI":"10.1126\/science.1099480"},{"key":"2019111814303061900_REF5","unstructured":"Fabbro D, Ruetz S, Bodis S, et al. PKC412\u2014a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des.2000;15: 17-28."},{"key":"2019111814303061900_REF6","doi-asserted-by":"crossref","unstructured":"Lennert K, Parwaresch MR. Mast cells and mast cell neoplasia: a review. Histopathology.1979;3: 349-365.","DOI":"10.1111\/j.1365-2559.1979.tb03017.x"},{"key":"2019111814303061900_","doi-asserted-by":"crossref","unstructured":"Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol.1991;96: 2S-4S.","DOI":"10.1111\/1523-1747.ep12468882"},{"key":"2019111814303061900_","unstructured":"Valent P. Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr.1996;108: 385-397."},{"key":"2019111814303061900_REF9","doi-asserted-by":"crossref","unstructured":"Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol.2003;122: 695-717.","DOI":"10.1046\/j.1365-2141.2003.04575.x"},{"key":"2019111814303061900_","doi-asserted-by":"crossref","unstructured":"Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med.2004;55: 419-432.","DOI":"10.1146\/annurev.med.55.091902.103822"},{"key":"2019111814303061900_REF11","doi-asserted-by":"crossref","unstructured":"Tefferi A, Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol.2004;11: 58-64.","DOI":"10.1097\/00062752-200401000-00009"},{"key":"2019111814303061900_REF12","doi-asserted-by":"crossref","unstructured":"Valent P, Ghannadan M, Akin C, et al. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur J Clin Invest.2004;34: 41-52.","DOI":"10.1111\/j.0960-135X.2004.01369.x"},{"key":"2019111814303061900_REF13","doi-asserted-by":"crossref","unstructured":"Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A.1995;92: 10560-10564.","DOI":"10.1073\/pnas.92.23.10560"},{"key":"2019111814303061900_","doi-asserted-by":"crossref","unstructured":"Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet.1996;12: 312-314.","DOI":"10.1038\/ng0396-312"},{"key":"2019111814303061900_","doi-asserted-by":"crossref","unstructured":"Longley BJ, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-kit catalytic domain mutations in distinct forms of human mastocytosis. Proc Natl Acad Sci U S A.1999;96: 1609-1614.","DOI":"10.1073\/pnas.96.4.1609"},{"key":"2019111814303061900_REF16","doi-asserted-by":"crossref","unstructured":"Fritsche-Polanz R, Jordan JH, Feix A, et al. Mutation analysis of C-KIT in patients with myelodys-plastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol.2001;113: 357-364.","DOI":"10.1046\/j.1365-2141.2001.02783.x"},{"key":"2019111814303061900_REF17","doi-asserted-by":"crossref","unstructured":"Feger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol.2002;127: 110-114.","DOI":"10.1159\/000048179"},{"key":"2019111814303061900_REF18","doi-asserted-by":"crossref","unstructured":"Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the protooncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product. J Clin Invest.1993;92: 1736-1744.","DOI":"10.1172\/JCI116761"},{"key":"2019111814303061900_REF19","unstructured":"Tefferi A, Pardanani A. Systemic mastocytosis: current concepts and treatment advances. Curr Hematol Rep.2004;3: 197-202."},{"key":"2019111814303061900_REF20","doi-asserted-by":"crossref","unstructured":"Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated forms of c-kit. Exp Hematol.2003;31: 686-692.","DOI":"10.1016\/S0301-472X(03)00112-7"},{"key":"2019111814303061900_","doi-asserted-by":"crossref","unstructured":"Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory type mutations. Blood.2002;99: 1741-1744.","DOI":"10.1182\/blood.V99.5.1741"},{"key":"2019111814303061900_REF22","unstructured":"Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther.2002;1: 1115-1124."},{"key":"2019111814303061900_REF23","doi-asserted-by":"crossref","unstructured":"Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood.2004;103: 3222-3225.","DOI":"10.1182\/blood-2003-11-3816"},{"key":"2019111814303061900_REF24","doi-asserted-by":"crossref","unstructured":"Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood.2003;102: 3093-3096.","DOI":"10.1182\/blood-2003-05-1627"},{"key":"2019111814303061900_","doi-asserted-by":"crossref","unstructured":"Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet.2003;362: 535-536.","DOI":"10.1016\/S0140-6736(03)14115-3"},{"key":"2019111814303061900_REF26","doi-asserted-by":"crossref","unstructured":"Pardanani A. Systemic mastocytosis: bone marrow pathology, classification, and current therapies. Acta Haematol.2005;114: 41-51.","DOI":"10.1159\/000085561"},{"key":"2019111814303061900_REF27","doi-asserted-by":"crossref","unstructured":"Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell.2005;7: 129-141.","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"2019111814303061900_REF28","doi-asserted-by":"crossref","unstructured":"Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res.1988;12: 345-355.","DOI":"10.1016\/0145-2126(88)90050-1"},{"key":"2019111814303061900_REF29","doi-asserted-by":"crossref","unstructured":"Sillaber C, Strobl H, Bevec D, et al. IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J Immunol.1991;147: 4224-4228.","DOI":"10.4049\/jimmunol.147.12.4224"},{"key":"2019111814303061900_REF30","doi-asserted-by":"crossref","unstructured":"Mayerhofer M, Aichberger KJ, Florian S, et al. c-kit D816V provides a strong signal for myelomastocytic differentiation and cluster formation in murine Ba\/F3 cells [abstract]. Blood.2004;104: 141a.","DOI":"10.1182\/blood.V104.11.485.485"},{"key":"2019111814303061900_REF31","doi-asserted-by":"crossref","unstructured":"Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr\/abl protein. Proc Natl Acad Sci U S A.1988;85: 9312-9316.","DOI":"10.1073\/pnas.85.23.9312"},{"key":"2019111814303061900_REF32","doi-asserted-by":"crossref","unstructured":"Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr\/Abl-transformed cells. Blood.2000;95: 2118-2125.","DOI":"10.1182\/blood.V95.6.2118"},{"key":"2019111814303061900_REF33","doi-asserted-by":"crossref","unstructured":"Valent P, Horny H-P, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Conference Report of \u201cYear 2000 Working Conference on Mastocytosis.\u201d Leuk Res.2001;25: 603-625.","DOI":"10.1016\/S0145-2126(01)00038-8"},{"key":"2019111814303061900_","unstructured":"Valent P, Horny H-P, Li CY, et al. Mastocytosis (mast cell disease). In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization (WHO) Classification of Tumours: Pathology & Genetics: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001: 291-302."},{"key":"2019111814303061900_","doi-asserted-by":"crossref","unstructured":"Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood.2002;100: 661-665.","DOI":"10.1182\/blood-2002-01-0203"},{"key":"2019111814303061900_REF36","doi-asserted-by":"crossref","unstructured":"Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD. Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression. Int Arch Allergy Immunol.2002;127: 137-139.","DOI":"10.1159\/000048185"},{"key":"2019111814303061900_REF37","doi-asserted-by":"crossref","unstructured":"Broudy VC, Lin N, Zsebo KM, et al. Isolation and characterization of a monoclonal antibody that recognizes the human c-kit receptor. Blood.1992;79: 338-346.","DOI":"10.1182\/blood.V79.2.338.338"},{"key":"2019111814303061900_REF38","unstructured":"Bu\u0308hring HJ, Ashman LK, Gattei V, et al. Stem-cell factor receptor (p145(c-kit)) summary report (CD117). In: Schlossmann SF, Boumsell L, Gilks W, et al, eds. Leucocyte Typing V: White Cell Differentiation Antigens. Vol 2. Oxford, United Kingdom: Oxford University Press; 1995: 1882-1888."},{"key":"2019111814303061900_REF39","doi-asserted-by":"crossref","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul.1984;22: 27-55.","DOI":"10.1016\/0065-2571(84)90007-4"},{"key":"2019111814303061900_REF40","doi-asserted-by":"crossref","unstructured":"Van Cruchten S, Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol.2002;31: 214-223.","DOI":"10.1046\/j.1439-0264.2002.00398.x"},{"key":"2019111814303061900_REF41","doi-asserted-by":"crossref","unstructured":"Schedle A, Samorapoompichit P, Fu\u0308reder W, et al. Metal ion-induced toxic histamine release from human basophils and mast cells. J Biomed Mater Res.1998;39: 560-567.","DOI":"10.1002\/(SICI)1097-4636(19980315)39:4<560::AID-JBM9>3.0.CO;2-H"},{"key":"2019111814303061900_REF42","doi-asserted-by":"crossref","unstructured":"Samorapoompichit P, Kiener HP, Schernthaner GH, et al. Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood.2001;98: 2580-2583.","DOI":"10.1182\/blood.V98.8.2580"},{"key":"2019111814303061900_REF43","unstructured":"Gorczyca W, Gong J, Darzynkiewicz Z. Detection of strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidal transferase and nick translation assays. Cancer Res.1993;53: 1945-1951."},{"key":"2019111814303061900_REF44","doi-asserted-by":"crossref","unstructured":"Walker PR, Carson C, Leblanc J, Sikorska M. Labeling DNA damage with terminal transferase: applicability, specificity, and limitations. Methods Mol Biol.2002;203: 3-19.","DOI":"10.1007\/978-1-59259-179-4_1"},{"key":"2019111814303061900_REF45","doi-asserted-by":"crossref","unstructured":"Escribano L, Diaz-Agustin B, Bellas C, et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res.2001;25: 563-570.","DOI":"10.1016\/S0145-2126(01)00050-9"},{"key":"2019111814303061900_REF46","doi-asserted-by":"crossref","unstructured":"Valent P, Schernthaner GH, Sperr WR, et al. Variable expression of activation-linked surface antigens on human mast cells in health and disease. Immunol Rev.2001;179: 74-81.","DOI":"10.1034\/j.1600-065X.2001.790108.x"},{"key":"2019111814303061900_REF47","doi-asserted-by":"crossref","unstructured":"Ghannadan M, Hauswirth AW, Schernthaner GH, et al. Detection of novel CD antigens on the surface of human mast cells and basophils. Int Arch Allergy Immunol.2002;127: 299-307.","DOI":"10.1159\/000057747"},{"key":"2019111814303061900_REF48","doi-asserted-by":"crossref","unstructured":"Growney JD, Clark JJ, Adelsperger J, et al. Activation mutations of human c-KIT resistant to imatinib are sensitive to the tyrosine kinase inhibitor PKC412. Blood.2005;106: 721-724.","DOI":"10.1182\/blood-2004-12-4617"},{"key":"2019111814303061900_REF49","doi-asserted-by":"crossref","unstructured":"Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol.2004;22: 3813-3825.","DOI":"10.1200\/JCO.2004.05.140"},{"key":"2019111814303061900_REF50","doi-asserted-by":"crossref","unstructured":"Cowan-Jacob SW, Guez V, Fendrich G, et al. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem.2004;4: 285-299.","DOI":"10.2174\/1389557043487321"},{"key":"2019111814303061900_REF51","doi-asserted-by":"crossref","unstructured":"Weisberg E, Griffin JD. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat.2003;6: 231-238.","DOI":"10.1016\/S1368-7646(03)00062-1"},{"key":"2019111814303061900_REF52","doi-asserted-by":"crossref","unstructured":"Gotlib J, Berube C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood.2005;106: 2865-2870.","DOI":"10.1182\/blood-2005-04-1568"},{"key":"2019111814303061900_REF53","doi-asserted-by":"crossref","unstructured":"Droogendijk HJ, Kluin-Nelemans JC, van Daele PLA. Imatinib mesylate in the treatment of systemic mastocytosis: a phase I\/II trial [abstract]. Blood.2004;104: 1516a.","DOI":"10.1182\/blood.V104.11.1516.1516"},{"key":"2019111814303061900_REF54","doi-asserted-by":"crossref","unstructured":"Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood.2003;102: 4270-4276.","DOI":"10.1182\/blood-2003-05-1699"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/2\/752\/1281274\/zh800206000752.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/2\/752\/1281274\/zh800206000752.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T19:56:51Z","timestamp":1683230211000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/2\/752\/131489\/PKC412-inhibits-in-vitro-growth-of-neoplastic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,15]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,1,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-07-3022","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,15]]}}}